Information Provided By:
Fly News Breaks for June 14, 2019
GBT
Jun 14, 2019 | 07:42 EDT
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Global Blood Therapeutics following release of the final Hope Phase 3 results for hemoglobin modifier voxelotor in sickle cell disease. The analyst expects the data to support "rapid approval and commercial success" in sickle cell. He notes that no patient discontinued due to an adverse event with the exception of a single patient in the placebo group.
News For GBT From the Last 2 Days
There are no results for your query GBT